Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.52 |
| ▸ | HTR3A | P46098 | 2/20 | 0.52 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.52 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.46 |
| ▸ | RXFP1 | Q9HBX9 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.39 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | ACACB | O00763 | 1/20 | 0.39 |
| ▸ | PPARG | P37231 | 4/20 | 0.39 |
| ▸ | PPARD | Q03181 | 4/20 | 0.39 |
| ▸ | PPARA | Q07869 | 3/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | SMO | Q99835 | 1/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL237705 | 0.80 | HTR1A (0.44) | HRH3HTR3ARXFP1HTR1AACACB | |
| SCHEMBL345053 | 0.79 | HRH3 (0.61) | HRH3HTR3AHRH4PDE10AHTR1A | |
| SCHEMBL239841 | 0.79 | HRH3 (0.61) | HRH3HTR3AHRH4PDE10AHTR1A | |
| SCHEMBL27829234 | 0.79 | HRH3 (0.47) | HRH3HTR3AHRH4PDE10AHTR1A | |
| SCHEMBL345184 | 0.77 | PDE10A (0.52) | HRH3HTR3AHRH4PDE10AHTR1A | |
| SCHEMBL346050 | 0.75 | HRH3 (0.56) | HRH3HTR3AHRH4PDE10AHTR1A | |
| SCHEMBL238256 | 0.75 | HTR3E (0.46) | HTR3APDE10AHTR3EHTR3BHTR3D | |
| SCHEMBL239984 | 0.74 | GRIN2D (0.38) | HRH3HTR3AHTR1AHTR3EHTR3B | |
| SCHEMBL27829233 | 0.74 | HRH3 (0.47) | HRH3HTR3AHRH4PDE10AHTR1A | |
| SCHEMBL1727924 | 0.73 | HRH3 (0.48) | HRH3HTR3AHRH4PDE10AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8912218-B2 | Alkylthiazol carbamate derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-12-16 | — | — | US | disclosed |
| US-8716289-B2 | Carbamate derivatives of alkyl-heterocycles, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2014-05-06 | — | — | US | disclosed |
| CN-102164920-B | Alkylthiazole carbamate derivatives, method for the production thereof and use thereof as FAAH enzyme inhibitors | SANOFI AVENTIS | 2013-12-25 | — | — | CN | disclosed |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2012-01-19 | — | — | US | disclosed |
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2012-01-05 | — | — | US | disclosed |
| CN-102216291-A | Carbamate derivatives containing alkyl-heterocycles, preparation and therapeutic use thereof | SANOFI AVENTIS | 2011-10-12 | — | — | CN | disclosed |
| US-8034818-B2 | Therapeutic uses of derivatives of piperidinyl- and piperazinyl-alkyl carbamates | SANOFI-AVENTIS (FR) | 2011-10-11 | — | — | US | disclosed |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2011-09-01 | — | — | US | disclosed |
| CN-102164920-A | Alkylthiazole carbamate derivatives, method for the production thereof and use thereof as FAAH enzyme inhibitors | SANOFI AVENTIS | 2011-08-24 | — | — | CN | disclosed |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | SANOFI-AVENTIS (FR) | 2007-06-21 | — | — | US | disclosed |
| US-7214798-B2 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2007-05-08 | — | — | US | disclosed |
| US-20060089344-A1 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | SANOFI-AVENTIS (FR) | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089344-A1 | Derivatives of piperidinyl-and piperazinyl-alkyl carbamates, preparation methods thereof and application of same in therapeutics | CLCN2, CNR2, RCC2 | HRH3 33/4885HTR3A 2346/4885HRH4 44/4885 |
| US-20110212963-A1 | ALKYLTHIAZOL CARBAMATE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | MET, ALK, REL | HRH3 42/4885HTR3A 1159/4885HRH4 19/4885 |
| US-20120015950-A1 | CARBAMATE DERIVATIVES OF ALKYL-HETEROCYCLES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | INTS9, CDK8, SCN8A | HRH3 50/4885HTR3A 2763/4885HRH4 72/4885 |
| US-20120004207-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL-AND PIPERIDINYL-ALKYL CARBAMATES | CLCN2, CLIC1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | HRH3 33/4885HTR3A 2303/4885HRH4 72/4885 |
| US-20070142350-A1 | THERAPEUTIC USES OF DERIVATIVES OF PIPERIDINYL- AND PIPERAZINYL-ALKYL CARBAMATES | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CBR3, H1-2 | HRH3 13/4885HTR3A 1876/4885HRH4 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.